Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 7: Primo ...

Truist raised the firm’s price target on Fresenius Medical (FMS) to $25 from $23 and keeps a Hold rating on the shares as ...

Fresenius Medical Care (NYSE:FMS – Free Report) had its price target lifted by Truist Financial from $23.00 to $25.00 in a research note published on Monday,Benzinga reports. Truist Financial ...

EQS-AFR: Fresenius Medical Care AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS – Free Report) in a report released on Friday morning. The brokerage issued a strong-buy rating on the stock. Several ...

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services. Its dialysis business is vertically ...

Fresenius is a strong buy with a 60% Return on Revenue potential in the next 3 years, driven by earnings growth and strategic ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Highlights,Short interest in Fresenius Medical Care decreased by 5.1% in December.,Hedge funds, including Wulff Hansen & Co., significantly raised their stakes in FMS.,The stock’s performance ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...